Drug Trial Radar · NCT07486024
Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Sep 11, 2026
Primary completion
Aug 2030
Study completion Feb 2032
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Viatris Inc.
- First posted
- Mar 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The FAST-MDR trial is an externally-controlled, multicentre trial with one prospective arm, evaluating the non-inferiority of the effectiveness of BPaLM in the interventional arm versus the effectiveness of the long, conventional regimen in a French historical cohort of MDR-TB patients (2006-2022). In light of recent WHO recommendations suggesting using BPaLM as a first choice for routine MDR-TB treatment and of the expected benefits of BPaLM over the standard treatment, there will be no internal comparator arm in the study.
Conditions
- MDR-TB
- Tuberculosis Multi Drug Resistant Active
- Antibiotic Resistance
- Mycobacterium Tuberculosis
Interventions
Bedaquiline Oral TabletDrug
Bedaquiline will be given as 400 mg once daily for 2 weeks and then 200 mg thrice weekly for the remaining 22 weeks
Bedaquiline Oral TabletDrug
Bedaquiline will be given as 200 mg once daily for 8 weeks and then 100 mg daily for the remaining 16 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effectiveness of BPaLM compared to conventional MDR-TB regimensTime frame: Day 0 to Month 18
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
CHU Amiens
Amiens, France · Recruiting
CHU Bichat - Claude-Bernard
Paris, France · Recruiting
Pitié-Salpêtrière Hospital - infectious and tropical diseases
Paris, France · Not yet recruiting
CHU Rennes
Rennes, France · Recruiting
CHU Toulouse - Hôpital Purpan
Toulouse, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.